Association of sodium-glucose cotransporter 2 inhibitors with post-discharge outcomes in patients with acute heart failure with type 2 diabetes: a cohort study
Main finding · HF readmission or cardiovascular deathResult — go to the resultAdjusted hazard ratio 0.90 95% CI 0.87–0.93Authors' conclusion
Among patients with type 2 diabetes, initiating SGLT2i treatment after an episode of acute heart failure was significantly associated with a reduced combined risk of heart failure readmission and cardiovascular mortality in a nationwide cohort reflecting routine clinical practice.
Study context
- Population
- Patients with T2D hospitalized for HF, Korean Health Insurance Review & Assessment database (2015–2020); mean (SD) age 74.1 (10.8) years; 56.1% womenof 56,343 hospitalized
- Participants
- 29,290 patients
- Exposure
- SGLT2i initiation during hospitalization or at discharge vs no SGLT2i
- SGLT2in = 818
- Outcome
- Post-discharge HF readmission or cardiovascular death
- Follow-up
- 1 year
Methodological detailsnationwide, propensity score-based inverse probability of treatment weighting
- Nationwide
- Propensity score-based inverse probability of treatment weighting
Main finding
HF readmission or cardiovascular death
Adjusted hazard ratio
0.90
95% CI 0.87–0.93
By group
SGLT2ivs Non-users
aHR 0.90 (95% CI 0.87–0.93)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | SGLT2i | Non-users | aHR (CI) | |
|---|---|---|---|---|
| HF readmission or cardiovascular death · 30 days | 7.0% | 7.7% | 0.74 (0.69–0.79) | |
| 0.512Adjusted hazard ratio (log scale) |
Original publication
Association of sodium-glucose cotransporter 2 inhibitors with post-discharge outcomes in patients with acute heart failure with type 2 diabetes: a cohort study. Cardiovasc Diabetol. Published 28 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →